LENZ Therapeutics, Inc.
LENZ Nasdaq
SEC CIK 1815776
Follow LENZ Therapeutics
Weekly email: filings, results
Revenue, last quarter
$3.4M
−72.9% vs same quarter last year
Net income
−$31M
−85.4% vs same quarter last year
EPS, diluted
−$0.99
−67.8% vs same quarter last year
Operating cash flow
−$22.3M
−159.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$82.1M |
| FY24 | −$49.8M |
| FY23 | −$70M |
| FY22 | −$101.1M |
| FY21 | −$70.8M |
| FY20 | −$68.4M |
| FY19 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$70M |
| FY24 | −$59.9M |
| FY23 | −$60.4M |
| FY22 | −$94.6M |
| FY21 | −$58.6M |
| FY20 | −$10.3M |
| FY19 | - |